Extracorporeal near-infrared-activated antimicrobial photodynamic therapy for pneumonia using an ICG-polymer formulation.

Biophotonics discovery Pub Date : 2026-08-13 eCollection Date: 2026-07-01 DOI:10.1117/1.BIOS.3.3.035002

Lorraine Gabriele Fiuza, Isabelle Almeida de Lima, Fernanda Alves, Michelle Barreto Requena, Vadila Giovana Guerra, Layla Pires, Cristina Kurachi, Natalia Mayumi Inada, Vanderlei Salvador Bagnato

{"title":"Extracorporeal near-infrared-activated antimicrobial photodynamic therapy for pneumonia using an ICG-polymer formulation.","authors":"Lorraine Gabriele Fiuza, Isabelle Almeida de Lima, Fernanda Alves, Michelle Barreto Requena, Vadila Giovana Guerra, Layla Pires, Cristina Kurachi, Natalia Mayumi Inada, Vanderlei Salvador Bagnato","doi":"10.1117/1.BIOS.3.3.035002","DOIUrl":null,"url":null,"abstract":"Significance: Pneumonia remains a global health challenge, exacerbated by antimicrobial resistance, which limits the effectiveness of conventional treatments. Antimicrobial photodynamic therapy (aPDT) has emerged as a promising alternative for lower respiratory infections; however, its in vivo performance is hindered by lung surfactant, which traps photosensitizers and reduces their ability to reach bacterial targets.Aim: To address this limitation, recent studies demonstrated that combining indocyanine green (ICG) with the polymer Gantrez AN-139 enhances photodynamic activity even in the presence of lung surfactants.Approach: We assessed the therapeutic potential of this formulation in a murine pneumonia model using pulmonary delivery followed by 808 nm infrared irradiation.Results: Nebulization of <math><mrow><mn>200</mn> <mtext> </mtext> <mi>μ</mi> <mi>M</mi></mrow> </math> ICG with 4% Gantrez AN-139 and irradiation at <math><mrow><mn>120</mn> <mtext> </mtext> <mi>J</mi> <mo>/</mo> <msup><mi>cm</mi> <mn>2</mn></msup> </mrow> </math> yielded the best results, reducing bacterial load by up to <math><mrow><mn>3</mn> <mtext> </mtext> <msub><mrow><mi>log</mi></mrow> <mrow><mn>10</mn></mrow> </msub> </mrow> </math> and improving survival to 80%, compared with 40% in controls.Conclusion: These findings validate the formulation and the procedure for further animal studies.","PeriodicalId":519981,"journal":{"name":"Biophotonics discovery","volume":"3 3","pages":"035002"},"PeriodicalIF":0.0000,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13557454/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biophotonics discovery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1117/1.BIOS.3.3.035002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Significance: Pneumonia remains a global health challenge, exacerbated by antimicrobial resistance, which limits the effectiveness of conventional treatments. Antimicrobial photodynamic therapy (aPDT) has emerged as a promising alternative for lower respiratory infections; however, its in vivo performance is hindered by lung surfactant, which traps photosensitizers and reduces their ability to reach bacterial targets.

Aim: To address this limitation, recent studies demonstrated that combining indocyanine green (ICG) with the polymer Gantrez AN-139 enhances photodynamic activity even in the presence of lung surfactants.

Approach: We assessed the therapeutic potential of this formulation in a murine pneumonia model using pulmonary delivery followed by 808 nm infrared irradiation.

Results: Nebulization of $200 μ M$ ICG with 4% Gantrez AN-139 and irradiation at $120 J / {cm}^{2}$ yielded the best results, reducing bacterial load by up to $3 \log_{10}$ and improving survival to 80%, compared with 40% in controls.

Conclusion: These findings validate the formulation and the procedure for further animal studies.

查看原文本刊更多论文

体外近红外激活抗菌光动力治疗肺炎使用icg聚合物配方。

意义：肺炎仍然是一项全球健康挑战，抗菌素耐药性限制了常规治疗的有效性，加剧了这一挑战。抗菌光动力疗法（aPDT）已成为下呼吸道感染的一种有希望的替代疗法；然而，其在体内的表现受到肺表面活性剂的阻碍，它会捕获光敏剂并降低其到达细菌目标的能力。目的：为了解决这一限制，最近的研究表明，将吲哚菁绿（ICG）与聚合物Gantrez AN-139结合，即使在肺表面活性剂存在的情况下，也能增强光动力活性。方法：我们评估了该制剂在小鼠肺炎模型中的治疗潜力，采用肺给药后808 nm红外照射。结果：2% Gantrez AN-139的200 μ M ICG雾化和120 J / cm2的辐照效果最好，细菌负荷减少高达3 log 10，存活率提高到80%，而对照组为40%。结论：这些发现验证了配方和进一步动物实验的程序。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biophotonics discovery

自引率

0.00%

发文量